Disease · MONDO_0000402
small cell carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. small cell carcinoma. Diseases, record MONDO_0000402. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000402
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- oat cell cancer, oat cell carcinoma, small cell NEC, small cell cancer, small cell car. (extrapulmonary), small cell carcinoma (extrapulmonary), small cell neuroendocrine carcinoma
- Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ETOPOSIDE | CHEMBL44657 | Small molecule | Approval | DailyMed | 7 | 6 | 6 | Drugs and targets |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| TOPOTECAN HYDROCHLORIDE | CHEMBL1607 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| NIBROZETONE | CHEMBL3526802 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TORIPALIMAB | CHEMBL4297843 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CATEQUENTINIB | CHEMBL4303201 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets129
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 129
See all 129 targetsTrials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | Phase 2 | 139 | 2025-03-17 | Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer | CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, GEMCITABINE, IRINOTECAN, NIBROZETONE, PACLITAXEL, PEMETREXED, VINORELBINE | Its record names the disease | ClinicalTrials.gov |
| NCT03896503 | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | Phase 2 | 104 | 2024-11-13 | Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma | BERZOSERTIB, TOPOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT02769832 | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | Phase 2 | 32 | 2023-07-21 | Small Cell Lung Cancer (SCLC) | GEMCITABINE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Phase 1/2 | 10 | 2024-01-03 | Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | DFP-13318, RUCAPARIB | Its record names the disease | ClinicalTrials.gov |
| NCT05566041 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer | Phase 3 | 292 | Carcinoma, Small Cell Lung | CARBOPLATIN, CISPLATIN, ETOPOSIDE, NIBROZETONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06441344 | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell | Phase 3 | 136 | SCLC, Maintenance Treatment | CARBOPLATIN, CATEQUENTINIB, CISPLATIN, ETOPOSIDE, TORIPALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00500422 | Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | Phase 1 | 134 | Solid Tumors | BORTEZOMIB, DOXORUBICIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06464068 | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA | Phase 2 | 66 | Extrapulmonary Small Cell Carcinoma | CARBOPLATIN, CISPLATIN, DURVALUMAB, ETOPOSIDE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT05760053 | Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma | Phase 2 | 33 | Toripalimab, First-line Treatment | CARBOPLATIN, CISPLATIN, ETOPOSIDE, TORIPALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06816394 | Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) | Phase 2 | 32 | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | TARLATAMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg vs Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg: Phase I Number of Participants With a Dose Limiting Toxicity (DLT) | 1 of 8 | 0 of 2 | 10 | NCT04209595 | Trial comparisons |
Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg vs Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 8 of 8 | 2 of 2 | 10 | NCT04209595 | Trial comparisons |
| Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg vs Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg: deaths from any cause | 7 of 8 | 2 of 2 | 10 | NCT04209595 | Trial comparisons |
| Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg vs Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg: serious adverse events | 3 of 8 | 2 of 2 | 10 | NCT04209595 | Trial comparisons |
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000402
GET https://conductscience.org/api/diseases/v1/MONDO_0000402/drugs?page=2